Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12/23, JAK inhibition, sphingosine …
L Sattler, SB Hanauer, L Malter - Current gastroenterology reports, 2021 - Springer
Abstract Purpose of the Review As treatment options for Inflammatory Bowel Disease (IBD)
expand each class of medication will have specific safety concerns and side-effect profiles …
expand each class of medication will have specific safety concerns and side-effect profiles …
[HTML][HTML] Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016
F Xu - MMWR. Morbidity and Mortality Weekly Report, 2018 - cdc.gov
Health-Risk Behaviors and Chronic Conditions Among Adults with Inflammatory Bowel Disease
— United States, 2015 and 2016 | MMWR Skip directly to site content Skip directly to page …
— United States, 2015 and 2016 | MMWR Skip directly to site content Skip directly to page …
Commercial whey products promote intestinal barrier function with glycomacropeptide enhanced activity in downregulating bacterial endotoxin lipopolysaccharides …
Cheese whey contains bioactive compounds which have shown multiple health-promoting
benefits. This study aimed to assess the commercial whey products (CWP) whey protein …
benefits. This study aimed to assess the commercial whey products (CWP) whey protein …
CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods
N Null, S Jain, C Bakolitsa, SE Brenner, P Radivojac… - Genome …, 2024 - cris.unibo.it
Background: The Critical Assessment of Genome Interpretation (CAGI) aims to advance the
state-of-the-art for computational prediction of genetic variant impact, particularly where …
state-of-the-art for computational prediction of genetic variant impact, particularly where …
Role of microRNA in inflammatory bowel disease: clinical evidence and the development of preclinical animal models
The dysregulation of microRNA (miRNA) is implicated in cancer, inflammation,
cardiovascular disorders, drug resistance, and aging. While most researchers study …
cardiovascular disorders, drug resistance, and aging. While most researchers study …
Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn's disease in the United States
CA Siegel, F Yang, S Eslava, Z Cai - Clinical and Translational …, 2020 - journals.lww.com
OBJECTIVES: Biologic therapies have been available for inflammatory bowel disease for>
20 years, but patient outcomes have not changed appreciably over this time period. To …
20 years, but patient outcomes have not changed appreciably over this time period. To …
The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease
KG Harris, EB Chang - Clinical Science, 2018 - portlandpress.com
Inflammatory bowel diseases (IBD) are a group of chronic diseases of increasing worldwide
prevalence characterized by gastrointestinal (GI) inflammation leading to debilitating …
prevalence characterized by gastrointestinal (GI) inflammation leading to debilitating …
International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS …
DT Rubin, C Sninsky, B Siegmund… - Inflammatory bowel …, 2021 - academic.oup.com
Background Inflammatory bowel diseases (IBD), including Crohn disease (CD) and
ulcerative colitis (UC), are complex disorders with multiple comorbidities. We conducted …
ulcerative colitis (UC), are complex disorders with multiple comorbidities. We conducted …
A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis
DE Peters, LD Norris, L Tenora, I Šnajdr… - Science translational …, 2023 - science.org
There is an urgent need to develop therapeutics for inflammatory bowel disease (IBD)
because up to 40% of patients with moderate-to-severe IBD are not adequately controlled …
because up to 40% of patients with moderate-to-severe IBD are not adequately controlled …
Competition for clinical trials in inflammatory bowel diseases
MS Harris, J Wichary, M Zadnik, W Reinisch - Gastroenterology, 2019 - gastrojournal.org
Over recent years, the inflam-matory bowel diseases (IBD), ulcerative colitis (UC) and
Crohn's disease (CD), have attracted major interest by academic and biopharmaceutical …
Crohn's disease (CD), have attracted major interest by academic and biopharmaceutical …